CWS
FOLD

Confluence Wealth Services’s Amicus Therapeutics FOLD Stock Holding History

Confluence Wealth Services’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-402
Closed -$4K – 564
2021
Q4 		$4K Buy
+402
New +$4.48K ﹤0.01% 1078

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Confluence Wealth Services's FOLD Position: Q1 2022 in Review

Confluence Wealth Services sold out of Amicus Therapeutics (FOLD) in Q1 2022, closing a stake of 402 shares — an estimated $4K sold.

Confluence Wealth Services first reported a position in FOLD in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 217 funds tracked by Wall St. Rank hold FOLD as of Q1 2022.

  • Confluence Wealth Services reported no remaining Amicus Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Confluence Wealth Services sold 402 Amicus Therapeutics shares in Q1 2022, an estimated $4K.
  • Confluence Wealth Services first reported a position in Amicus Therapeutics in Q4 2021 and held it in 1 quarter.
  • Confluence Wealth Services's Amicus Therapeutics position peaked at $4K in Q4 2021.
  • 217 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2022.

Based on Confluence Wealth Services's 13F filing for Q1 2022, filed 26 Apr 2022.